Cochrane · systematic review · CD005139
Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration
Solomon, SD, Lindsley, K, Vedula, SS, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 57.1%High 5 · 35.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings: anti‐VEGF treatment versus control
Population: people with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gain of 15 or more letters visual acuity at 1 year Summary of findings: anti‐VEGF treatment vs control | RR 4.19 [2.32, 7.55] | 6 studies · 2667 participants | Moderate Downgraded: imprecision |
Loss of fewer than 15 letters visual acuity at 1 year Summary of findings: anti‐VEGF treatment vs control | RR 1.4 [1.27, 1.55] | 6 studies · 2667 participants | High |
Mean change in visual acuity at 1 year (number of letters) Summary of findings: anti‐VEGF treatment vs control | no estimate extracted | 4 studies · 2508 participants | Moderate Downgraded: inconsistency |
Reduction in central retinal thickness at 1 year Summary of findings: anti‐VEGF treatment vs control | no estimate extracted | NR | No studies |
Mean change in vision‐related quality of life Summary of findings: anti‐VEGF treatment vs control | MD 6.69 [3.38, 9.99] | 2 studies · 1134 participants | Moderate Downgraded: imprecision |
Serious systemic adverse events at 1 year Summary of findings: anti‐VEGF treatment vs control | RR 0.17 [0.01, 4.24] | 6 studies · 2667 participants | Moderate |
Serious ocular adverse events at 1 year Summary of findings: anti‐VEGF treatment vs control | RR 0.52 [0.03, 8.25] | 6 studies · 2667 participants | Moderate |
Summary of findings: bevacizumab versus ranibizumab
Population: people with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gain of 15 or more letters visual acuity at 1 year Summary of findings: bevacizumab vs ranibizumab | RR 0.95 [0.81, 1.12] | 8 studies · 3144 participants | High |
Loss of fewer than 15 letters visual acuity at 1 year Summary of findings: bevacizumab vs ranibizumab | RR 1 [0.98, 1.02] | 8 studies · 3144 participants | High |
Mean change in visual acuity at 1 year (number of letters) Summary of findings: bevacizumab vs ranibizumab | no estimate extracted | 9 studies · 3190 participants | High |
Reduction in central retinal thickness at 1 year Summary of findings: bevacizumab vs ranibizumab | no estimate extracted | 6 studies · 2693 participants | High |
No problems in quality of life domains at 1 year Summary of findings: bevacizumab vs ranibizumab | RR 0.96 [0.9, 1.04] | 1 study · 548 participants | Moderate |
Serious systemic adverse events at 1 yearb Summary of findings: bevacizumab vs ranibizumab | RR 1.15 [0.99, 1.34] | 6 studies · 3365 participants | Moderate |
Serious ocular adverse events at 1 year Summary of findings: bevacizumab vs ranibizumab | RR 0.51 [0.05, 5.62] | 1670 participants | Moderate |